title: Effects of antiviral agents and HBV genotypes on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients.
abstract: OBJECTIVE
  To evaluate the effects of antiviral agents and HBV genotypes on intrahepatic covalently closed circular DNA (ccc DNA) in HBeAg-positive chronic hepatitis B patients.
  
  
  METHODS
  Seventy-one patients received lamivudine (n = 35), or sequential therapy with lamivudine- interferon alpha 2b (IFN-alpha 2b, n = 24) for 48 wk, or IFN-alpha 2b (n = 12) for 24 wk. All subjects were followed up for 24 wk. Intrahepatic ccc DNA was measured quantitatively by PCR. HBV genotypes were analyzed by PCR-RFLP.
  
  
  RESULTS
  Sequential lamivudine- INF-alpha therapy, lamivudine and INF-alpha monotherapy reduced ccc DNA of 1.7 log, 1.4 log and 0.8 log, respectively (P < 0.05). Seventeen out of the 71 patients developed HBeAg seroconversion, the reduction of ccc DNA in the HBeAg seroconversion patients was more significant than that in the HBeAg positive patients (3.0 log vs 1.6 log, P = 0.0407). Twenty-four weeks after antiviral therapy withdrawal, 16 patients had a sustained virological response, the baseline intrahepatic ccc DNA in the patients with a sustained virological response was significantly lower than that in the patients with virological rebound (4.6 log vs 5.4 log, P = 0.0472). HBV genotype C accounted for 85.9% (n = 61), and genotype B for 14.1% (n = 10), respectively, in the 71 patients. There was no significant difference in the change of ccc DNA level between HBV genotypes C and B (2.1 log vs 1.9 log).
  
  
  CONCLUSIONS
  Forty-eight week sequential lamivudine-INF-alpha therapy and lamivudine monotherapy reduce ccc DNA more significantly than 24-wk INF-alpha monotherapy. Low baseline intrahepatic ccc DNA level may predict the long-term efficacy of antiviral treatment. HBV genotypes C and B have no obvious influence on ccc DNA load.
authors.affiliation: Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China.
authors.forename: Hai-Ying
authors.initials: HY
authors.lastname: Lu
authors.forename: Li-Wei
authors.initials: LW
authors.lastname: Zhuang
authors.forename: Yan-Yan
authors.initials: YY
authors.lastname: Yu
authors.forename: Chong-Wen
authors.initials: CW
authors.lastname: Si
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.forename: Jian-Jun
authors.initials: JJ
authors.lastname: Zhang
authors.forename: Zheng
authors.initials: Z
authors.lastname: Zeng
authors.forename: Xin-Yue
authors.initials: XY
authors.lastname: Chen
authors.forename: Zhong-Hou
authors.initials: ZH
authors.lastname: Han
authors.forename: Yong
authors.initials: Y
authors.lastname: Chen
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000494:pharmacology*; D004270:DNA, Circular / Q000378:metabolism*; D005260:Female; D005786:Gene Expression Regulation; D005838:Genotype; D006509:Hepatitis B / Q000821:virology*; D006513:Hepatitis B e Antigens / Q000096:biosynthesis*; D006515:Hepatitis B virus / Q000235:genetics*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000378:metabolism; D019259:Lamivudine / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D013997:Time Factors
chemical_list: D000998:Antiviral Agents; D004270:DNA, Circular; D006513:Hepatitis B e Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D019259:Lamivudine